Potential of the gastric motility drug lorglumide in prostate cancer imaging

European Journal of Pharmaceutical Sciences

Volumn 45, Issue 5, 2012, Pages 575-580

  Sturzu, Alexander ^a   Sheikh, Sumbla ^a   Klose, Uwe ^a   Echner, Hartmut ^a   Kalbacher, Hubert ^a   Deeg, Martin ^a   Nägele, Thomas ^a   Horger, Marius ^a   Schwentner, Christian ^a   Ernemann, Ulrike ^a   Heckl, Stefan ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Bifunctional contrast agent; Cholecystokinin A receptor; Lorglumide; Magnetic resonance imaging

Indexed keywords

CHOLECYSTOKININE A RECEPTOR; FLUORESCENT DYE; GADOTERIC ACID; LORGLUMIDE; PEPTIDES AND PROTEINS; UNCLASSIFIED DRUG;

ARTICLE; CELL LINE; CONFOCAL LASER MICROSCOPY; FLUORESCENCE ACTIVATED CELL SORTING; GLIOMA; HUMAN; HUMAN CELL; IMAGE ANALYSIS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

CELL LINE, TUMOR; CONTRAST MEDIA; FLOW CYTOMETRY; FLUORESCENT DYES; GASTROINTESTINAL AGENTS; GASTROINTESTINAL MOTILITY; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MICROSCOPY, CONFOCAL; OSTEOSARCOMA; PROGLUMIDE; PROSTATIC NEOPLASMS; RHODAMINES;

EID: 84857914276     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2011.12.011     Document Type: Article

References (18)

1. W.J. Catalona, D.S. Smith, T.L. Ratliff, K.M. Dodds, D.E. Coplen, J.J. Yuan, J.A. Petros, and G.L. Andriole Measurement of prostate-specific antigen in serum as a screening test for prostate cancer N. Engl. J. Med. 324 1991 1156 1161 (Erratum in: N. Engl. J. Med. 325 (1991) 1324.)
2. W.M. Deserno, M.G. Harisinghani, M. Taupitz, G.J. Jager, J.A. Witjes, P.F. Mulders, C.A. Hulsbergen van de Kaa, D. Kaufmann, and J.O. Barentsz Urinary bladder cancer: preoperative nodal staging with ferumoxtran-10-enhanced MR imaging Radiology 233 2004 449 456 (Pubitemid 39423804)
3. B. Djavan, E. Eckersberger, J. Finkelstein, H. Sadri, S.S. Taneja, and H. Lepor Prostate-specific antigen testing and prostate cancer screening Prim. Care 37 2010 441 459, vii
4. C. González-Puga, A. García-Navarro, G. Escames, J. León, M. López-Cantarero, E. Ros, and D. Acuña-Castroviejo Selective CCK-A but not CCK-B receptor antagonists inhibit HT-29 cell proliferation: synergism with pharmacological levels of melatonin J. Pineal. Res. 39 2005 243 250 (Pubitemid 41337804)
5. M.G. Harisinghani, M.A. Saksena, P.F. Hahn, B. King, J. Kim, M.T. Torabi, and R. Weissleder Ferumoxtran-10-enhanced MR lymphangiography: does contrast-enhanced imaging alone suffice for accurate lymph node characterization? Am. J. Roentgenol. 186 2006 144 148 (Pubitemid 46100376)
6. M.G. Harisinghani, and R. Weissleder Sensitive, noninvasive detection of lymph node metastases PLoS Med. 1 2004 e66
7. M.K. Herrington, and T.E. Adrian On the role of cholecystokinin in pancreatic cancer Int. J. Pancreatol. 17 1995 121 138
8. J.S. Jones Saturation biopsy for detecting and characterizing prostate cancer BJU Int. 99 6 2007 1340 1344 (Pubitemid 47164825)
9. F. Makovec, M. Bani, R. Cereda, R. Chisté, M.A. Pacini, L. Revel, L.A. Rovati, L.C. Rovati, and I. Setnikar Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists Arznei-forschung. 37 1987 1265 1268 (Pubitemid 17151199)
10. R. Moonka, W. Zhou, and R.H. Bell Jr. Cholecystokinin-A receptor messenger RNA expression in human pancreatic cancer J. Gastrointest. Surg. 3 1999 134 140
11. T. Petit, K.K. Davidson, R.A. Lawrence, D.D. von Hoff, and E. Izbicka Neuropeptide receptor status in human tumor cell lines Anticancer Drugs 12 2001 133 136 (Pubitemid 32207362)
12. P. Portincasa, R. Brandonisio, A. Di Ciaula, V. Maggi, M. Chiloiro, and G. Palasciano The effect of a novel CCK-antagonist (lorglumide) on human and guinea pig gallbladder strips: a tensiometric study Boll. Soc. Ital. Biol. Sper. 66 1990 567 573
13. B.F. Roettger, D. Ghanekar, R. Rao, C. Toledo, J. Yingling, D. Pinon, and L.J. Miller Antagonist-stimulated internalization of the G protein-coupled cholecystokinin receptor Mol. Pharmacol. 51 1997 357 362 (Pubitemid 27118469)
14. V. Sancho, A. Di Florio, T.W. Moody, and R.T. Jensen Bombesin receptor-mediated imaging and cytotoxicity: review and current status Curr. Drug Delivery 8 2011 79 134
15. D. Schilling, T. de Reijke, B. Tombal, A. de la Taille, J. Hennenlotter, and A. Stenzl The Prostate Cancer gene 3 assay: indications for use in clinical practice BJU Int. 105 4 2010 452 455
16. Steinmetz, N.F., Ablack, A.L., Hickey, J.L., Ablack, J., Manocha, B., Mymryk, J.S., Luyt, L.G., Lewis, J.D., 2011. Intravital Imaging of Human Prostate Cancer Using Viral Nanoparticles Targeted to Gastrin-Releasing Peptide Receptors. Small. doi:10.1002/smll.201000435.
17. A. Sturzu, M. Regenbogen, U. Klose, H. Echner, A. Gharabaghi, and S. Heckl Novel dual labelled nucleus-directed conjugates containing correct and mutant nuclear localisation sequences Eur. J. Pharm. Sci. 33 2008 207 216
18. S.A. Watson, D.L. Morris, L.G. Durrant, J.F. Robertson, and J.D. Hardcastle Inhibition of gastrin-stimulated growth of gastrointestinal tumour cells by octreotide and the gastrin/cholecystokinin receptor antagonists, proglumide and lorglumide Eur. J. Cancer 28A 1992 1462 1467